Holen Sie sich die Stockscreener-App
4.52
5.83%
-0.28
Aclaris Therapeutics Inc Aktie (ACRS) Neueste Nachrichten
Aclaris Therapeutics (ACRS) price target increased by 12.65% to 9.64 - MSN
ACRS: Multiple late-stage immunology assets advance toward key 2024 milestones, backed by robust funding - TradingView
ACRS: Multiple innovative I&I therapies advance toward key Phase 2b milestones in 2026 - TradingView
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates - MSN
MSN Money - MSN
H.C. Wainwright Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Guggenheim Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Oppenheimer Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Stifel raises Aclaris Therapeutics price target to $4 on pipeline By Investing.com - Investing.com Nigeria
Stifel raises Aclaris Therapeutics price target to $4 on pipeline - Investing.com
Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference - The Manila Times
Aclaris: Q1 Earnings Snapshot - theheraldreview.com
Aclaris Therapeutics (ACRS) Quarterly Loss Near US$20 Million Reinforces Bearish Earnings Narrative - Sahm
Aclaris Therapeutics (NASDAQ: ACRS) deepens loss while boosting R&D - Stock Titan
Aclaris Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update - Investing News Network
Craig-Hallum Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Aclaris Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Aclaris Therapeutics | 8-K: Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update - Moomoo
Aclaris (NASDAQ: ACRS) posts Q1 2026 loss but boosts cash runway - Stock Titan
Aclaris says cash lasts through 2028 with key skin, asthma data due - Stock Titan
This Applied Materials Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
Aclaris Therapeutics Is Maintained at Overweight by Piper Sandler - Moomoo
Guggenheim initiates coverage of Aclaris Therapeutics (ACRS) with buy recommendation - MSN
Aclaris (ACRS) CMO vesting 36,375 RSUs with 9,330 shares tax withheld - Stock Titan
Guggenheim Initiates Aclaris Therapeutics(ACRS.US) With Buy Rating, Announces Target Price $12 - Moomoo
Piper Sandler Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Raises Target Price to $11 - Moomoo
Aclaris Reports Phase 1a Results for ATI-052, Advances Pipeline - MyChesCo
Aclaris Therapeutics Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth - Yahoo Finance
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Aclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific Antibody CandidatesSlideshow (NASDAQ:ACRS) 2026-04-28 - Seeking Alpha
Aclaris Therapeutics Updates ATI-052 Phase 1 Data, Picks ATI-2138 for Phase 2b in Lichen Planus - MarketBeat
Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4R? Bispecific Antibody, and Announces Lichen Planus as Lead Indication f - Investing News Network
Aclaris Posts Strong Phase 1a ATI-052 Data, Sets Lichen Planus As Lead Indication For ATI-2138 - RTTNews
Aclaris Therapeutics says positive full top line results from Phase 1a clinical trial of ATI-055 - marketscreener.com
Aclaris Reports Positive ATI-052 Phase 1a Trial Results - TipRanks
Aclaris reports phase 1a trial results for ATI-052 antibody - Investing.com
Aclaris reports phase 1a trial results for ATI-052 antibody By Investing.com - Investing.com Canada
Aclaris Therapeutics announced that the Phase 1B clinical trial of its drug candidate ATI-052 is currently actively recruiting patients. - Bitget
Aclaris (NASDAQ: ACRS) touts ATI-052 data, targets lichen planus with ATI-2138 - Stock Titan
Aclaris Therapeutics Announces Positive Full Top Line - GlobeNewswire
Aclaris Therapeutics Insider Sold Shares Worth $1,359,000, According to a Recent SEC Filing - marketscreener.com
0.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):